South Asians and Europeans react differently to common drugs

(Medical Xpress) -- A University of Sydney PhD student has discovered the different diets and lifestyles of South Asians compared to Europeans could lead to the two groups requiring very different doses of medicines commonly used to treat illnesses such as depression and psychosis.

Vidya Perera, a final year PhD student in the Faculty of Pharmacy, has found that people from could need lower doses of these medicines because they are likely to have lower levels of CYP1A2, an enzyme that metabolises drugs.

"Vegetables such as cabbages, cauliflower and broccoli are known to increase levels of CYP1A2, as was demonstrated in this study and previous studies in people of European background. The lower levels of CYP1A2 in , however, appears to be due to the common practice of cooking these vegetables in curries using ingredients such as cumin and tumeric, ingredients known to inhibit the enzyme, overriding the effect of the vegetables," Mr Perera explained.

Mr Perera has just been declared the NSW winner of the AusBiotech/GlaxoSmithKline Student Excellence Awards as a result of his research.

"I started out looking for between the two groups to account for the differences in CYP1A2 activity. What was fascinating to discover is that genetic differences only accounted for 3 per cent of variability in CYP1A2 activity, while environment and accounted for 35 percent of the differences," Mr Perera said.

A total of 332 people took part in the study - 166 South Asians and 166 Europeans. CYP1A2 levels were measured by giving participants a caffeine tablet, and analysing CYP1A2 in saliva samples four hours later. Demographic, dietary and lifestyle information was obtained using a questionnaire.

"Most drugs are approved in clinical trials conducted in Europe and North America using healthy, middle-aged European men," Mr Perera explained. "This is the first study to look at CYP1A2 activity in South Asians. Understanding the correct dose of a medicine is crucial to achieving beneficial results and avoiding adverse drug reactions."

Professor Andrew McLachlan, Associate Dean (Research) in the Faculty of Pharmacy and Mr Perera's PhD supervisor, commented on the significance of this research.

"The development and testing of medicines is a global enterprise. The highest population growth is occurring in South Asia, yet we know relatively little about how to translate research findings between different populations of people."

"This research, for the first time, unpacks the complex interplay of factors that can affect how people breakdown and eliminate medicines from their body."

"Past research has attributed differences between people from different geographical regions to result from genetic differences. This important research highlights how dietary and cultural factors can impact on pharmacological response."

Mr Perera will travel to Adelaide this weekend to compete before a panel of judges in the national final of the AusBiotech/GlaxoSmithKline Student Excellence Awards. He will present his research on Sunday, with the winner to be announced on Monday.

AusBiotech 2011 is the annual conference of AusBiotech and the premier biotechnology and life sciences conference for Australia and the Asia-Pacific, attracting over 1400 delegates from across the world each year.

(GSK) is a global research-based pharmaceutical and healthcare company. It collaborates with local researchers and doctors to discover new ways of treating and preventing disease. Mr Perera is the recipient of the Peter Coates Postgraduate Scholarship in Ethnopharmacology, supported by GSK.

Provided by University of Sydney

3.7 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

Genetic variants associated with caffeine intake identified

Apr 06, 2011

Two genes in which variation affects intake of caffeine, the most widely consumed stimulant in the world, have been discovered. A team of investigators from the National Cancer Institute, Harvard School of Public Health, ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments